NOVOZYMES A/S Received a Patent for SPRAY-DRIED LACTOBACILLUS STRAINS/CELLS — research analysis
Identify the Novozymes-linked Indian record and family
The legacy GIPResearch article identifies Indian application 2424/MUMNP/2013, titled A Method for Producing Composition with Spray-Dried Lactobacillus Strains/Cells, and reports Indian patent 316778. An identifiable international-family document, WO2012168468A1, concerns spray-dried Lactobacillus cells and their use in relation to Helicobacter pylori. The international publication's recorded priority is June 2011, and the corresponding application was filed through the PCT route in June 2012. Its listed original assignee is OrganoBalance GmbH, with a later listed connection to Novozymes Berlin GmbH. This does not prove the current ownership of the Indian right. The Indian filing, final grant claims and live maintenance status need direct registry confirmation before publication as current legal findings.
Source for this point: Google Patents — WO2012168468A1 Lactobacillus cells (Patent publication aggregation; not authoritative for current legal status).
Explain the reported technological distinction
Lactobacillus cells can be processed by techniques including drying to support storage and formulation. The historical article presents the invention as using spray-dried bacterial cells with specified properties relevant to interactions with H. pylori. The research question is whether the drying process causes a reproducible, technically significant change in the cells' behavior when compared with fresh cultures or earlier dried products. It is not enough to say that a probiotic composition is beneficial. The relevant experimental record should specify the bacterial strain, preparation conditions, viable and nonviable cell measures where applicable, storage stability, aggregation assay design and the actual measured comparison. A reported laboratory interaction must not be converted into a claim of proven clinical treatment efficacy.
Read independent claims before summarizing protection
The international abstract may refer generally to spray-dried Lactobacillus strains and their uses, but a patent claim can be much narrower. Examine whether the independent claims are directed to cells, a specific production method, compositions, treatment-related uses where allowable or a combination of defined properties. Record numerical features, strain identifiers, drying parameters and any exclusionary wording. Verify whether the Indian grant contains amendments that do not appear in the first international publication. Build a side-by-side table listing each claim limitation, its description support and any relevant applicant response during prosecution. A claim directed to one bacterial phenotype should not be represented as an exclusive right over all probiotic Lactobacillus products.
Determine reproducibility and biological-material evidence
The technical effect may depend on strain properties, fermentation stage, drying temperature, carrier materials, residual moisture, rehydration method and measurement conditions. These details affect whether another laboratory can reproduce the alleged behavior. If a particular biological material is not publicly available and cannot be adequately described, patent-deposit rules may be relevant; WIPO's Budapest Treaty and EPO disclosure guidance explain the general mechanism. Check for accession numbers and biological identifiers in the actual filing rather than assuming every named probiotic strain required a deposit. A technical-review table should separate what is disclosed, what is experimentally demonstrated and what remains a proposed explanation. This guards against interpreting the word 'strain' as proof of a unique biological deposit.
Source for this point: WIPO — Budapest Treaty summary (Official treaty guidance).
Reconcile historical applicants and legal ownership
The appearance of OrganoBalance, Novozymes Berlin and Novozymes A/S in related sources requires a careful entity and assignment chronology. A family database may list a present assignee based on recorded filings, corporate succession or data enrichment, but that alone is not a verified assignment chain in India. Retrieve official ownership entries and relevant transfer documents if available. Compare filing and priority dates, later family extensions and maintenance records in the target countries. The WIPO publication number is an important family locator, not a global enforceable patent. A valid scope analysis needs the country's granted claims and a current legal status check from the authority responsible for that right.
Separate the examiner's objection from the patent's scientific merits
The original article says the Indian examiner raised a section 3(d) objection to routine spray-drying steps or new use of a known substance, and that the applicant argued improved co-aggregation with H. pylori. These accounts are leads for prosecution research, not independently verified quotations of the full record. Obtain the examiner's communication, applicant's response, proposed amended claims and final decision. Evaluate whether the alleged comparison used an appropriate control and whether the claim language actually reflects the asserted technical difference. Avoid concluding that any claimed treatment was clinically effective merely because the application received a reported grant. Patent examination, regulatory proof and medical practice are distinct analyses.
Develop a parameter-to-effect comparison table
A useful original table can compare freshly cultured cells, conventional dried cells and the claimed spray-dried preparation. Columns should identify strain identity, process parameters, storage conditions, viability measures, aggregation methodology, relevant results and evidence sources. Where specific numbers are unavailable, the report should say so rather than supply illustrative values as experimental results. A second table can compare other probiotic formulations against the claimed limitations, noting whether documents concern the same organisms or only similar therapeutic objectives. Such analysis helps distinguish technical novelty from a broad consumer claim about microbiome health. The database should also record family documents and later citations with explicit retrieval dates.
What the available record supports and leaves open
The searchable international family supports a concrete focus on spray-dried Lactobacillus cell technology, and the preserved WordPress source reports the Indian application and grant identifiers. The current Indian grant text, legal status, ownership and examiner's complete findings are not independently verified here. No medical efficacy recommendation or commercial freedom-to-operate opinion follows from these materials. The final dossier should pair the precise claim chart with authenticated patent-office records and separate laboratory observations from clinical conclusions. This approach protects the historical page's useful subject matter while avoiding an unsupported current claim about patent enforceability or therapeutic outcomes.
Keep organism identity and corporate ownership distinct
An organism's scientific name is not the same as an accession number or a proprietary strain identity. A family-level comparison should avoid equating documents solely because both mention Lactobacillus. It should also distinguish the named applicant in a PCT publication from a later corporate proprietor and from a licensee using a product. Confirm assignments and priority references before merging records. In evaluating the reported aggregation behavior, note which strain and assay conditions were actually measured. A laboratory method using one strain may not support a conclusion about all related bacteria. The same analytical care is needed for patent-status information: the international publication is evidence of disclosed subject matter, not of an active Indian right.
Original evidence-to-decision matrix
| Research dimension | Evidence to inspect | Interpretation boundary |
|---|---|---|
| Family identity | WO2012168468A1 and Indian legacy identifiers | Assignment and Indian claim version pending |
| Spray-drying process | Strain and process-condition documentation | Assay cannot be generalized to all species |
| Functional comparison | Fresh versus spray-dried cell tests | Clinical efficacy is a separate question |
Research readiness checklist
- Match Indian 2424/MUMNP/2013 to WO2012168468.
- Confirm strain, assay and drying-process limitations.
- Verify assignments between historical corporate names.
- Use Indian office for live status, not family database alone.
References and primary sources
- Google Patents — WO2012168468A1 Lactobacillus cells. Patent publication aggregation; not authoritative for current legal status.
- EPO — 2026 deposit of biological material. Official examination guidance.
- WIPO — Budapest Treaty summary. Official treaty guidance.
- GIPResearch.com — preserved Novozymes historical article. Original site assertion; not independent patent-office verification.
General research only. Any current grant, claim, ownership, legal status or professional opinion requires verification of official records and the facts of the particular matter. Full disclaimer


How to patent fintech inventions
Gen AI Innovations
What is Extended Reality
How to patent artificial intelligence based innovations
Patent claim drafting